Pharmabiz13h
Boehringer Ingelheim India and RED.Health ambulance services sign MoU to strengthen emergency stroke care in pre-hospital setup in India
Our Bureau, Mumbai Thursday, November 21, 2024, 17:30 Hrs [IST] ...
Pharmabiz8h
SynaptixBio notes gene silencing therapy market set to boom, company develops ASO to spur treatment for rare, deadly disease
Oxford-based SynaptixBio, which is developing an antisense oligonucleotide (ASO) to ‘silence’ the expression of a single mutated gene, has noted that the gene silencing market is set to grow ...
Pharmabiz12h
Abbott unveils new recommendations and partnerships to improve diversity in clinical trials
Abbott announced that, in the third year of its multi-million-dollar Diversity in Clinical Trials initiative, the company has published 'Advancing Diversity in Clinical Trials' to share strategies to ...
Pharmabiz13h
Syngene embarks on evaluating the bioequivalence of an injectable for type-2 diabetes and weight management
Our Bureau, Bengaluru Thursday, November 21, 2024, 17:45 Hrs [IST] ...
Pharmabiz14h
Illumina to release new version of its flagship cancer research assay, TruSight Oncology 500 v2
Illumina to release new version of its flagship cancer research assay, TruSight Oncology 500 v2: San Diego Thursday, November 21, 2024, 16:00 Hrs [IST] Illumina, Inc., a global le ...
Pharmabiz16h
Abbott launches AVEIR VR leadless pacemaker system in India to treat patients with slow heart rhythms
Abbott launches AVEIR VR leadless pacemaker system in India to treat patients with slow heart rhythms: Our Bureau, Mumbai Thursday, November 21, 2024, 14:15 Hrs [IST] Abbott, a gl ...
Pharmabiz14h
Stalwarts in ophthalmology and optometry felicitated with Dr B T Maskati Memorial Awards at 10th Super Specialty Lens Symposium 2024
Stalwarts in ophthalmology and optometry felicitated with Dr B T Maskati Memorial Awards at 10th Super Specialty Lens Symposium 2024: Our Bureau, Mumbai Thursday, November 21, 202 ...
Pharmabiz12h
argenx advances clinical development of efgartigimod SC in idiopathic inflammatory myopathies
SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced the decision to continue development of efgartigimod subcutaneous (SC) ...
Pharmabiz16h
Pfizer’s Hympavzi receives European marketing approval to treat adults and adolescents with severe haemophilia A or B without inhibitors
Pfizer Inc. announced that the European Commission (EC) has granted marketing authorization for Hympavzi (marstacimab) for the routine prophylaxis of bleeding episodes in patients 12 years of age and ...
Pharmabiz15h
NIH-led scientific team defines elements of brain-based visual impairment in children
NIH-led scientific team defines elements of brain-based visual impairment in children: Bethesda, Maryland Thursday, November 21, 2024, 15:00 Hrs [IST] Experts convened by the Nati ...
Pharmabiz16h
Tagomics announces a multiomic profiling co-marketing agreement with Agilent Technologies
Tagomics announces a multiomic profiling co-marketing agreement with Agilent Technologies: Cambridge, UK Thursday, November 21, 2024, 14:00 Hrs [IST] Tagomics Ltd., a pioneering b ...
Pharmabiz17h
FIP publishes new regional roadmaps for prioritising antimicrobial
FIP publishes new regional roadmaps for prioritising antimicrobial: Our Bureau, Bengaluru Thursday, November 21, 2024, 13:30 Hrs [IST] International Pharmaceutical Federation (FIP ...